Work

Care of Patients With Inflammatory Bowel Disease With Inadequate Response or Intolerance to Upadacitinib

Year: 2025

Type: article

Abstract: Upadacitinib (UPA) is an oral selective inhibitor for Janus kinase 1 approved for the treatment of tumor necrosis factor (TNF)-alpha–experienced patients with inflammatory bowel disease (IBD). Phase III trials of UPA showed remission rates approaching 50% with real-world studies reporting rates approaching 80%. These response rates represent important progress toward breaking the ‘therapeutic ceiling’ that has plagued IBD treatment, particularly for anti-TNF–experienced patients [1-4]. However, in clinical practice, the challenge has become managing those intolerant or unresponsive to UPA.

Source: Gastro Hep Advances

DOI: 10.1016/j.gastha.2025.100648

Authors: Lynn Kobeissi, Kristi Briggs, Caya McFalls, Mark Lazarev, Joanna Melia

Institutions: Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000